Silvio E Inzucchi
Overview
Explore the profile of Silvio E Inzucchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
416
Citations
25094
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Inciardi R, Lu H, Claggett B, Desai A, Jhund P, Lam C, et al.
JACC Heart Fail
. 2025 Mar;
PMID: 40047763
Background: Patients with severe heart failure (HF) experience debilitating clinical symptoms and worse cardiovascular (CV) outcomes with an excess mortality risk. Objectives: The authors aimed to assess the prevalence, CV...
2.
Aggarwal R, Bhatt D, Szarek M, Cannon C, Leiter L, Inzucchi S, et al.
Lancet Diabetes Endocrinol
. 2025 Feb;
PMID: 39961315
Background: Sodium-glucose co-transporter (SGLT)-2 inhibitors have shown consistent benefit in improving heart failure-related outcomes but not ischaemic cardiovascular events such as myocardial infarction or stroke. We assessed if the dual...
3.
Ambrosy A, Sauer A, Patel S, Windsor S, Borlaug B, Husain M, et al.
ESC Heart Fail
. 2024 Dec;
PMID: 39716939
Aims: Sodium-glucose co-transporter-2 (SGLT2) inhibitors improve health status and outcomes in the setting of heart failure (HF) across the range of ejection fraction (EF). Baseline kidney disease is common in...
4.
Inzucchi S, Tan X, Liang Y, Yedigarova L, Xie L, de Havenon A
Diabetes Ther
. 2024 Dec;
16(2):187-203.
PMID: 39688779
Introduction: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have demonstrated cardiovascular benefits in trials involving high-risk patients with type 2 diabetes (T2D), while dipeptidyl peptidase 4 inhibitors (DPP-4is) have not....
5.
Ostrominski J, Hojbjerg Lassen M, Claggett B, Miao Z, Inzucchi S, Docherty K, et al.
Eur Heart J
. 2024 Nov;
PMID: 39568016
Background And Aims: Individuals with heart failure (HF), other forms of cardiovascular disease, or kidney disease are at increased risk for the development and adverse health effects of diabetes. As...
6.
Selvaraj S, Patel S, Sauer A, McGarrah R, Jones P, Kwee L, et al.
Circ Heart Fail
. 2024 Oct;
17(11):e011980.
PMID: 39421941
Background: Mechanisms of benefit with SGLT2is (sodium-glucose cotransporter-2 inhibitors) in heart failure (HF) remain incompletely characterized. Dapagliflozin alters ketone and fatty acid metabolism in HF with reduced ejection fraction though...
7.
Harrington J, McGuire D, Inzucchi S
JACC Heart Fail
. 2024 Oct;
12(11):1827-1829.
PMID: 39387772
No abstract available.
8.
Pabon M, Vaduganathan M, Claggett B, Chatur S, Siqueira S, Marti-Castellote P, et al.
Eur J Heart Fail
. 2024 Sep;
26(12):2532-2540.
PMID: 39300780
Aims: Patients with heart failure (HF) with improved ejection fraction (HFimpEF) may face residual risks of clinical events that are comparable to those experienced by patients with HF whose left...
9.
Butt J, Shen L, Inzucchi S, Docherty K, Jhund P, Martinez F, et al.
JACC Heart Fail
. 2024 Sep;
12(11):1946-1948.
PMID: 39269393
No abstract available.
10.
Inzucchi S, Arai A
J Am Coll Cardiol
. 2024 Jul;
84(6):558-560.
PMID: 39084830
No abstract available.